The Open Insulin mouvement was started in California with the intention of bringing the price of insulin down.

The project's current goal is to bring new generic manufacturers into the industry, by lowering the cost/technical barriers to entry. For the most part, this is a problem created as each manufacturer is required to get the insulin-producing bacteria approved under the FDA or EMA.

So, under the project DISCO, BioFoundry produced a number of insulin producing bacteria using open-source knowledge and has published all of their work online. They hope to work with NFPs, philanthropic investors and potential manufacturers in order to get one of these approved under Biosimilar regulation.

Once this is done, we will provide these open-source bacteria free of charge to all pharmaceutical companies, generic manufacturers and start-ups that want to get involved in Insulin manufacturing. With a pre-approved bacteria, their main focus can be on obtaining GMP approval for their manufacturing facilities!

For more information please contact

Find an actor

BioAlps Networking Day 201829.11.2018

L'événement aura lieu au SICHH le 29 novembre 2018 au blueFACTORY à Fribourg

AMAL Therapeutics raises 33.2 million dollars

The Geneva-based startup just announced the completion of its Series B financing round, raising in total CHF 33.2...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn